Atopic dermatitis is a common inflammatory skin disease that causes intense itching and rash, significantly impacting patient's quality of life. Traditional treatments have been nonspecific, often unsuccessful, and accompanied by various side effects. New therapeutic approaches encompass diverse strategies, including targeted agents, local and systemic pharmacological therapies, phototherapy, and psychosocial support. Local pharmacological therapy includes the use of corticosteroids, immunomodulators such as tacrolimus, and topical antibiotics for secondary infections. Systemic corticosteroids are used only as a short-term option for acute exacerbations of moderate to severe disease, avoiding long-term use to prevent rebound effects. Biological therapy, such as dupilumab, targets specific inflammatory mediators, while JAK inhibitors modulate multiple cytokines in the pathogenesis of the disease. Systemic traditional immunosuppressants like cyclosporine and methotrexate are used for more severe forms of the disease but require strict monitoring due to potential side effects. Innovative therapies such as topical JAK inhibitors and PDE4 inhibitors show promising results. Additionally, experimental therapies like roflumilast, difamilast, tapinarof, and brepocitinib, as well as bacteriotherapy with Staphylococcus hominis A9, are being investigated as potential options in the treatment of atopic dermatitis. In addition to the question of the availability of certain therapeutic options, an individual approach to each patient is necessary in the control of atopic dermatitis.